View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
April 9, 2020

Tiziana Life Sciences develops Covid-19 therapy candidate

Tiziana Life Sciences has developed an investigational technology for the treatment of Covid-19.

The approach involves the use of a handheld inhaler or nebuliser to directly deliver anti-IL-6 receptor (anti-IL-6R) monoclonal antibodies (mAbs) into the lungs.

This is expected to support the company’s development of a fully-human anti-IL6R mAb, TZLS-501, to treat Covid-19.

Tiziana Lifesciences chairman Gabriele Cerrone said: “Direct delivery of anti-IL-6R mAb to the lungs using a portable handheld inhaler or nebuliser is a rapid and immediate therapy for children and adults infected with Covid-19.

“Importantly, this treatment with our fully human anti-IL-6R mAb (TZLS-501) has the potential to be a long-term therapy to halt progression and reduce mortality in patients with Covid-19, as a portion of the population may not opt to utilise a vaccine.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU